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ABSTRACT
VEGF INDUCED DIFFERENTIATION OF GINGIVAL STEM CELLS TO
ENDOTHELIAL CELLS IN VITRO
DEGREE DATE: JUNE 21, 2019 Garima Gupta, D.D.S.
COLLEGE OF DENTAL MEDICINE NOVA SOUTHEASTERN UNIVERSITY
Directed by: Dr. Umadevi Kandalam, Associate Professor, Department of Pediatric
Dentistry, NSU College of Dental Medicine.

Background: Birth defects that result in structural malformation of major organs
are one of the major causes of mortality in children. Tissue engineering and
regenerative medicine (TERM) strategies are particularly beneficial for the
pediatric patients to correct these defects owing to their greater regenerative
capacity compared to the adult population. Limited availability of pediatric patient’s
auto-transplantation of organs makes TERM strategies as a promising alternative
to conventional clinical procedures that utilize the grafts. Recent developments in
stem cells technologies, there is an enormous potential for TERM in correcting
birth defects and enhancing the life span in young population. However, the major
challenge to the craniofacial bone tissue engineering is the repair and regeneration
of critical size bone defects accompanied by functional vascular network.
Insufficient vasculature in regenerated bone is the main causes of large graft
failure, leading to inner graft necrosis and lack of integration with the host tissue.
While, it is well established that human gingiva derived mesenchymal stem cells
(GMSCS) are robust source of osteogenic precursors in bone regenerative TERM,
it is unknown if GMSCS also can differentiate into endothelial cells. The aim of this
study was to explore the potential of GMSCS to differentiate into endothelial cells.
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Methods: GMSCs were cultured under standard conditions. The angiogenic
differentiation was induced administering Vascular Endothelial Growth Factor
(VEGF). The expression of endothelial marker gene expression was measured by
using quantitative PCR method. A functional tube formation assay was performed
to assess the endothelial differentiation. Immunofluorescence was conducted to
detect the surface marker protein CD31.
Results: Our results showed a dose dependent increase in the expression of the
endothelial marker genes, PECAM-1, VCAM-1, KDR, FLT-1 and PCDH12. The
tube formation assay revealed the ability to form capillary structures in the cells
induced with 10 and 50ng/ml VEGF. The data on Immunofluorescence
demonstrated the distinct presence of CD31 surface marker.
Conclusions: Our results showed that GMSCS have the potential to differentiate
into endothelial cells. Thus, they serve as sources for programmed angiogenic and
osteogenic cells to contribute for the regeneration of the vascularized bone to
make a paradigm-shift in stem cell therapy.

Key words: Gingiva derived stem cells, Vascular endothelial growth factor,
Endothelial cells, Angiogenic differentiation, Craniofacial defect
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CHAPTER 1 INTRODUCTION
1.1 Craniofacial Bone Formation Key Considerations
Bone is a dynamic and highly vascularized tissue that contains extracellular matrix
composed of inorganic and organic elements that contains a number of types of
cell that are responsible for its metabolism.1 The formation of bone is multi-step
process with the interactions among various cells, extracellular matrix and organic
and inorganic molecules. In particular, during craniofacial bone development,
many biophysical forces, particularly mechanical load and locally released growth
factors are important regulatory factors.

Additionally, craniofacial skeleton

involved in specific function such as protection of brain and optic tract, while
facilitating mastication.2
1.2 Clinical Relevance
Birth defects that result in structural malformation of major organs are one of the
major causes of mortality in children. Craniofacial bone defects due to congenital
anomalies, cancers, and trauma and fractures are most common. While the birth
defects with congenital malfunctions are 2-3%, the prevalence of craniofacial
fractures in pediatric population is 58% of total fractures annually. While treatment
of cranial vaults needs permanent protection, reconstruction of segmental defects
requires restoration of mechanical integrity and temporal joint function. Unlike adult
patients, reconstruction of these mandibular and maxillo-facial bones in growing
babies require a proper understanding of the changes in the bone architecture to
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achieve optimal restoration of mastication, deglutition, and cosmetic issue. Thus,
the medical cost associated to repair of these defects, in particular the critical size
defects are over $2.5 billion/annum.3,4
1.3 Critical Size Defects and Current Treatment Modalities
A critical size bone defect is a large void in a bone beyond a critical healing
threshold, which cannot heal spontaneously. Attempting the repair in the absence
of bone grafts can impede the healing processes accompanied by osteogenesis,
which results in formation of fibrous connective tissue rather than bone warrants
the need of bone grafts.5

Currently, 2.2 million bone graft procedures are

performed around the world each year to repair the critical size defects.3 The
current gold standard treatment for reconstruction of critical size bone defect in the
craniofacial region is the implantation of autologous bone graft. Bone graft from
extra oral surgical harvest site commonly includes tibia and ilium. However, for
pediatric patients, graft harvest from autologous sites increases the additional risk
and morbidity of a second surgical procedure, the donor site morbidity and low
availability. Allografts, on the other hand, are concerned of risk for viral infections.
In addition, there is increased unpredictable outcome using the bone grafts, when
bone defect size is greater than 4 cm.6 All these drawbacks associated with grafts
call for the development of stem cell-based tissue engineering strategies as a
promising alternative way to regenerate bone.4,7-11
1.4 Bone Tissue Engineering
Human stem cell-based tissue engineering emerged as a viable option for the
regeneration of bone even in large craniofacial skeletal defects. There are three
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mains components of the “golden triad” of tissue engineering which includes cells,
growth factors and scaffolds6 (Figure 1). However, the challenges in bone tissue
engineering include induction of proper vasculature at the defect site in the
regenerated bone tissue.

Figure 1: Essential Components of Tissue Engineering

1.5 Significance of Vascularization in Bone Regeneration
The clinical success of bone tissue engineering lies on developing a functional/vital
bone with efficient vascularization. Bone formation indeed can progress
successfully if there is adequate vascularization at the site. In addition to the bone
formation, vasculature is also essential for bone remodeling during fracture healing
and therefore, angiogenesis is a key component in bone repair.12,13 Defective
angiogenesis and any alteration in the vascular supply can result in osteonecrosis,
3

osteomyelitis and delayed fracture healing or non- union.12,14 Osteonecrosis or
avascular necrosis happens when there is inadequacy of blood supply to the bone,
leading to death of bone cells. Osteomyelitis is an infection within the bone, which
is mainly caused by poor vascularization.12 Thus, bone vasculature is not only
essential for regeneration, remodeling and homeostasis but is also essential for
maintaining the functional integrity and longevity in the host.13-16 While the gold
standard autologous bone grafts have a pre-existing vascular network that meets
the demand of oxygen and nutrients supply, the engineered grafts are, in general,
incapable of generating sufficient vasculature. Vascularization supports bulk
transport of nutrients and convective oxygen transport. However, although
spontaneous vascularization does happen in the host to the graft, the vessel ingrowth is too slow to provide adequate nutrient and oxygen transport to the cells
in the deeper regions. Therefore, the engineered grafts have to rely mainly on
passive diffusion of nutrient and oxygen, which is often insufficient, resulting in
graft

failure.

Several

strategies

have

been

experimented

to

enhance

vascularization including pre-vascularization of scaffolds and utilizing two coculture methods, where endothelial cells will be co-cultured with stem cells.
1.6 Currently Available Techniques to Induce the Vascularization in
Regenerating Bone Tissue
There are numerous methods to increase vascularization in bone tissue
engineering; 1) combination of scaffold and angiogenic growth factors, and 2) exvivo pre-vascularization (i.e. co-culture of endothelial and osteogenic cells)
technique. However, both techniques have pros and cons, as shown below
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1.6.1 Combination of Scaffold and Angiogenic Growth Factors
A method of increasing vascularization in bone regeneration engineering by
scaffold combined with angiogenic growth factors (VEGF, FGF). Hydrogels and
other soft materials have been developed as suitable matrix materials for
osteogenesis and angiogenesis due to their characteristic of loading with cells at
relatively high density and retaining cell viability for longer period. 17 Nonetheless,
there are some drawbacks associated with this technique, including, disruption of
hydrogel structure and poor integration with the host tissue. 6 Although,
incorporation of the angiogenic growth factors onto the scaffold has been shown
to accelerate vascularization, it has been considered as a relatively inefficient
process for bone formation, and presents the difficulty in selecting proper dosage
of growth factor onto the scaffold with co-culturing between mature endothelial
cells and osteogenic cells. These shortcomings include limited in vitro expansion
of the endothelial cells.2 It is also concerned if multiple different cell types can grow
in concert to develop a structured bone tissue in the same ex-vivo culture. An
another approach in the co-culture is to use different ratios of each cell type, but
the main problem in this technique is to explore a way to identify different cell
types.7
1.6.2 An ex-vivo Pre-vascularization (i.e., Co-Culture of Endothelial and
Osteogenic Cells)
This technique utilizes co-culture of mature endothelial cells and osteogenic cells.
Although mature differentiated endothelial cells may be used for bone tissue
regeneration in combination of osteogenic cells, there are few pitfalls in co-
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culturing between mature endothelial cells and osteogenic cells. These
shortcomings include limited capacity to expand endothelial cell in vitro.2 It is also
concerned if multiple different cell types can grow in concert to develop a
structured bone tissue in the ex-vivo co-culture. Another approach in the coculture is to use different ratios of each cell type, but the main problem in this
technique is to explore a way to identify different cell types.7
1.7 Proposed Method to Induce Vascularization (GMSCs to Endothelial cells)
Based on the possible drawbacks of aforementioned techniques, we proposed in
this study to differentiate mesenchymal stem cells derived from human gingiva
(GMSCs) into endothelial progenitor cells (EPC) via stimulation with vascular
endothelial growth factor (VEGF). In that way, it will reduce the drawbacks
associated with transplantation of ex vivo co-cultured osteoblasts and endothelial
cells in a scaffold, which require appropriate ratio of both cell types and other
techniques using specially designed scaffolds.2 The endothelial progenitor cells
(EPC) are the ones with enhanced proliferative capacity and generates all subsets
of endothelial cell lineage upon differentiation. It has been found that EPC have a
higher survival rate as compared to mature endothelial cells (most commonly used
human umbilical vein endothelial cells, HUVECs).7 Furthermore, EPC have been
shown to be 10 times more proliferative than HUVECs.12
The stem cell source that contains both osteogenic and endothelial progenitor cells
is considered to be the most advantageous cell source. 2 Our lab has already
established the osteogenic potential of GMSCs. By this method, it would be
possible to use gingival stem cells as the cellular source for both osteogenic and
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vasculogenic progenitor cells, rather than adding exogenous endothelial and
osteoblast cell types to enhance angiogenesis during bone regeneration.
1.8 Gingival Mesenchymal Stem Cells (Cells Used in This Study)
In this study, we chose to use GMSCs. These cells are of special interest as they
serve a promising cellular source especially in craniofacial tissue regeneration.
90% of the GMSCs are derived from cranial neural crest cells and they differentiate
into cartilage and bone to form vast majority of craniofacial structures.4,13,14
Moreover, mesenchymal stem cells deriving from gingival tissues are minimally
invasive and are easily accessible18-22 (Figure 2). GMSCs have the ability to
proliferate faster than bone marrow stem cells, exhibits a stable morphology even
after extended passaging and have potent immunomodulatory characteristics. 18,19
Furthermore, neural crest originated stem cells like GMSCs might be more efficient
in regenerating bone in craniofacial region, when compared to the bone marrow
derived stem cells and may show better tissue acceptability than MSCs from other
tissues.13,14,22-25
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Figure 2: Sources of oral stem/progenitor cells isolated. DFSCs: dental follicle stem cells,
G-MSCs: gingival mesenchymal stem/progenitor cells, PDLSCs: periodontal ligament stem
cells, SHEDs: stem cells from the human exfoliated deciduous teeth, DPSCs: dental pulp
stem cells, BM-MSCs: bone marrow mesenchymal stem cells, and SCAP: stem cells from
the apical papilla (Reference: Fawzy El-Sayed KM, Dörfer CE. Gingival Mesenchymal
Stem/Progenitor Cells: A Unique Tissue Engineering Gem)

1.9 Growth Factors
Growth factors are biological macromolecules which play an important role in
regulating cell growth, differentiation and migration by targeting specific cellular
receptors. Angiogenic growth factors are commonly expressed in response to
injury and are produced by inflammatory cells and stromal cells to stimulate growth
of blood vessels. There are several angiogenic growth factors that include vascular
endothelial growth factor (VEGF), fibroblast growth factor (FGF), tumor necrosis
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growth factor (TNF-α), transforming growth factor beta (TGF-β), and the
angiopoietins. Among these, the most commonly considered proangiogenic factor
is vascular endothelial growth factor (VEGF).6,13,26,27
1.10 VEGF
The VEGF family consists of seven members: VEGF-A, VEGF-B, VEGF-C, VEGFD, VEGF-E, VEGF-F, PIGF. All of the 7 members share common homology
domain. VEGF original name was vascular permeability factor as it increases
microvascular permeability and fenestration. VEGF has multiple functions in
conditioning of angiogenesis as well as during angiogenesis processes. It
stimulates proliferation, migration of endothelial cells which results in the formation
of new blood vessels. Furthermore, studies have a shown that VEGF also
facilitates tube formation and engages in differentiation of endothelial progenitor
cells.6,13,26,27
1.11 Endothelial Cells
Studies have shown that endothelial cells can enhance bone regeneration ability.
Endothelial cells are the key cellular element that compose blood vessels and
capillaries (Figure 3). Endothelial cells are directly related to angiogenesis and
provide the pre-requisite for bone regeneration.7
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Figure 3: Endothelial cells

1.12 Mechanism how VEGF Stimulates Endothelial Cell Formation
VEGF is an angiogenic growth factor that works by binding with its two- cognate
receptor type tyrosine kinases, VEGFR1, VEGFR2 which, in turn, elicits cell
signals to induce angiogenesis.13
VEGF activates the phosphorylation of histone deacetylase 7 (HDAC7) via a
PKC/PKD1 pathway. HDAC7 is mainly restricted in the nucleus of endothelial cells.
HDAC7 phosphorylation stimulates nuclear export of HDAC7, which leads to
activation of VEGF responsive genes. RCAN2 and Nur77 are the VEGF regulated
genes required for migration and proliferation of endothelial cells.28 In summary,
VEGF signaling activates phosphorylation of HDAC7 and it regulates the
expression of VEGF responsive genes involved in angiogenesis.
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28

(Figure 4)

Figure 4: Mechanism of VEGF stimulating angiogenesis (Reference: Wang S, Li X, Parra M,
Verdin E, Bassel-Duby R, Olson EN. Efficient Differentiation of Bone Marrow Mesenchymal
Stem Cells into Endothelial Cells in Vitro)

1.13 Endothelial Marker Genes Used in This Study
The angiogenic differentiation of gingival stem cells were identified by the
expression of these endothelial marker genes: VCAM-1, PCDH12, VEGF
receptors (FLT1 and KDR), PECAM-1. Following are the endothelial markers that
have been evaluated.
1.13.1 Vascular Cell Adhesion Molecule-1(VCAM-1)/ CD106
This is the main endothelial receptor that plays an important role in mediating
adhesion of leukocytes to vascular endothelium. In addition to that, it also engages
in regulation of T-lymphoblast movement through endothelial venular walls.
Hence, it elicits cell signal transduction in between leukocyte and endothelial. 29
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1.13.2 Protocadherin 12 (PCDH12)/ VE cadherin
PCDH12 is a transmembrane protein mainly located at intercellular junctions.
Intercellular junctions have been shown to control some part of the endothelial
permeability to plasma proteins and circulating cells. Its expression is
characteristically noticed in endothelial cells. It is mainly responsible for calcium
dependent cell to cell adhesion.30,31
1.13.3 VEGF Receptors
1.13.3a FLT1/ VEGFR-1
VEGF regulates endothelial cell cycle through modulating molecular signal
pathways. The most significant effect of VEGF receptor-1 is controlling the cell
migration by regulating actin reorganization via the activation of p38 MAK kinase.
In addition to that, it also triggers activation and movement of monolayer
phagocytes across an endothelial cell monolayer. This interaction generates
chemotactic response in polymorphonuclear cells.26,32,33 (Figure 5)
1.13.3b KDR/ VEGFR-2
KDR promotes cell migration by controlling cell adhesion and mediates DNA
synthesis of endothelial cells via the activation of ERK1/2. Furthermore, it also
enhances vascular permeability during angiogenesis by stimulating the synthesis
of Platelet activating factor (PAF).26,32,33 (Figure 5)
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Figure 5: VEGF Receptors 1 and 2 (Reference: Sharma A, Bandello F, Kuppermann B,
Makam D, Research Efforts are going beyond targeting VEGF)

1.13.4 Platelet Endothelial Cell Adhesion Molecule-1(PECAM-1)/CD31
PCAM-1 is a transmembrane glycoprotein located on the blood endothelial cells,
platelets and on leukocytes. It has been shown to play a major role in
angiogenesis. It facilitates leukocyte movement through endothelial intercellular
junction during inflammation. 34-36
1.14 Innovation
Angiogenesis play a major role in functional bone regeneration. The current gold
standard protocol for the repair of critical size defects is the standard autografts.
13

Due to limitations associated with autografts, and allografts, stem cell-based tissue
engineering emerged as a viable approach to regenerate biological tissue
substitute for critical bony defects.

4,7-11

Mesenchymal stem cells (MSCs) from

different origins (For example; bone marrow, adipose tissue cells, urine) have been
shown to differentiate to endothelial cells following supplementation of vascular
endothelial growth factor (VEGF) in media.7-9,11 Limited studies have addressed
on orofacial tissue derived mesenchymal stem cells. It has been shown that
deriving stem cells from Orofacial tissues are minimally invasive and easily
accessible. The origin of GMSCs is from neural crest cells and they differentiate
into cartilage and bone to form craniofacial skeleton.4 Although, a technological
development is required to regenerate a highly vascularized and functional bone
in craniofacial region, to the best of our knowledge, none of the study has ever
addressed such a technique to differentiate GMSCs to endothelial cells in the
regenerated bone tissue. In this project, for the first time, we propose to
differentiate gingival stem cells to endothelial progenitor cells by supplementing
with VEGF. This project will be innovative in terms of developing a highly
vascularized and vital bone in the craniofacial region by differentiating GMSCs into
endothelial cells. It will eliminate drawbacks associated with co-culturing (that is,
co-culture of endothelial and osteogenic cells) technique. And also, it would be
possible to use gingival stem cells as the single cell source to enhance
angiogenesis during bone regeneration.

14

1.15 Objectives
The long-term goal of this project is to develop in-vitro pre-vascularized bone tissue
constructs which will be transplanted to the large defect for regeneration of bone
with sufficiently functional vascular networks. Thus, the translational significance
of this project represents the novel tissue engineering approach to regenerate a
highly vascularized and vital bone during bone regeneration in the craniofacial
region.
1.16 Specific Aim
The aim of this study is to examine the effects of VEGF on induction of in vitro
differentiation of gingival stem cells into endothelial cells.

15

CHAPTER 2 MATERIALS AND METHODS
2.1 Materials
Commercially available Recombinant Human VEGF, PECAM antibody were
purchased from R&D Systems (Minneapolis, MN) was used for the study. Human
Umbilical Vein Endothelial cells and were obtained from Lonza, (Allendale, NJ).
Primers used for quantitative PCR were obtained from Life Technologies. All other
required lab supplies were acquired from Sigma (St. Louis, MO).
2.2 Overall Study Design
The methods for isolation of gingival stem cells from human gingiva tissue has
already been established in our laboratory. The gingival tissue was obtained from
the NSU clinics following the guidelines of Institutional Review Board (IRB). In this
study, cryopreserved GMSCs were revived and the cells from 5 donors from male
and female have been used for all experiments. Cells were cultured under
standard culture conditions. Cells that have reached 70-80 % confluency were
induced with different concentrations of angiogenic medium (Dulbecco’s modified
Eagle Medium (DMEM) + 10% fetal bovine serum (FBS) + 1% antibiotics + VEGF
10, 50, 100 ng/mL) for one week. Human Umbilical Vein Endothelial cells
(HUVECs) were used as a positive control. The endothelial cell differentiation was
measured by quantitative PCR, immunofluorescence, tube formation assays. In
addition to that, scratch assay was performed to determine the migration of
endothelial cells. (Figure 6)
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Figure 6: Overall Methodology Design

2.3 Cell Culture and Characterization of GMSCs
The GMSCs obtained from human gingival tissues were cultured in 75cm² culture
flasks in growth medium (DMEM) supplemented with 10% FBS and 1% antibiotic)
and were incubated at 37°C in 5% CO2 atmosphere. After 72 hours of culture,
non-adherent cells were removed.37 The growth medium was changed every 2
days. The cells obtained from passage 2 were subjected to Flow-cytometric
analysis to confirm positive to mesenchymal markers CD44, CD73, CD90, and
CD105 and negative to CD34 (hematopoietic stem cells).20 These specific markers
were measured at the facilities at University of Miami using a fluorescent activated
cell sorter FACAria IIIu (BD Biosciences, San Jose, CA) with adjusted florescence
compensation setting.
17

2.4 VEGF Treatment to GMSCs
A recombinant human VEGF protein (Source: Spodoptera frugiperda, Sf 21
(baculovirus) - derived Ala27-Arg191) obtained from R n D systems, Minneapolis,
MN (catalogue # 293-VE-050) with a purity of >97%, with endotoxin level <0.01
EU per 1 μg was used for this study.
Gingival stem cells at 70- 80% confluency were treated with angiogenic
differentiation medium (DMEM, 10% fetal bovine serum, 1% antibiotic
supplemented with different concentrations of VEGF-10, 50, 100 ng/ ml) for 7 days.
Medium was changed every 2 days.10 The cells without VEGF treatment, and
HUVECs were designated as negative and positive control groups respectively
(Table 1). Cell morphology was monitored after induction with VEGF. Table 1
represents control and experimental groups studied for the study.

Control Groups
Human Umbilical vein endothelial
cells (HUVECs) - Positive control
Undifferentiated Gingival stem
Cells - Negative control

Experimental Group
10 ng/ml VEGF treated Gingival Stem
Cells
50 ng/ml VEGF treated Gingival Stem
Cells
100 ng/ml VEGF treated Gingival Stem
Cells

Table1: Control and Experimental Groups with HUVECs as positive control
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2.5 Scratch Assay
This assay typically involves culturing a confluent cell monolayer and then
displacing a group of cells by creating a scratch through the monolayer. In a 12
well plate 1x105 per well GMSCs were seeded and these were maintained at 37 °C
and 5% CO2 for 24 h to permit cell adhesion and the formation of a confluent
monolayer. These confluent monolayers were then scored with a 1ml sterile pipette
tip to leave a scratch of approximately 0.4–0.5 mm in width. Culture medium was
then immediately removed (along with any dislodged cells). The removed medium
was replaced with a fresh medium which served as control group. 50ng/ml VEGF
was supplemented to the experimental group. The cell migration was monitored at
1,4 and 17 hours. The cell migration was then analyzed microscopically by
capturing images at the beginning and at the regular intervals to see the
endothelial cell migration for closing the scratch.38 39 (Figure 7)
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Figure 7: Scratch Assay: The technique involves basic steps 1) cell seeding and
preparation; 2) making a linear thin scratch “wound” (creating a gap) 3) data acquisition
through microscopic image capturing and gap measurement at each time point; and 4) data
analysis. (Reference: Grada A, Otero-Vinas M, Prieto-Castrillo F, Obagi Z, Falanga V.
Research Techniques Made Simple: Analysis of Collective Cell Migration Using the Wound
Healing Assay)

2.6 Gene Expression by Quantitative PCR
Cells differentiated for 7 days were harvested and lysed in Trizol. The RNA was
isolated using Trizol (Invitrogen, Carlsbad, CA) extraction method established in
our laboratory and quantified. CDNA was prepared using high capacity reverse
transcription kit (life Science Technologies, Carlsbad, CA) according to
manufacturer’s recommendations.40 The expression of endothelial marker genes
VEGF receptors VCAM-1, KDR, PCDH12, FLT-1, and PECAM-1 were measured
using qPCR (Figure 8). The primers used are listed in Table 2.
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Figure 8: Quantitative PCR Gene Expression Studies

Serial #
1
2
3
4
5
6

Gene

Gene expression
assay used
Hs01065279
Hs01003372
Hs00176676
Hs01052961
Hs01007986
Hs00194899

PECAM-1
VCAM-1
KDR
FLT-1
PCDH12
B-Actin

Table 2: Primers used in Quantitative PCR

2.7 Immunofluorescence
The GMSCs treated with or without 50ng/ml VEGF were cultured for 7 days and
subsequently fixed with 4% pre-chilled (4°C) paraformaldehyde. The cells were
incubated at room temp for 15 mins and were rinsed 3 times with ice cold PBS for
21

5 mins each. The cells were incubated with 2 % BSA, 22.52 mg/ mL glycine in
PBST (PBS + 0.1 % Tween 20) for 60 mins to block unspecific binding of the
antibodies. After that, diluted primary antibody (PECAM-1) was added into the cells
in each well containing 1% BSA in PBST and kept for overnight incubation in 4º C.
Cells were washed with PBS 3 times for 5 mins each followed by incubating with
secondary antibody (Goat Anti-mouse IgG Alexa Fluoro-Plus 488). After
incubation, the cells were washed with PBS. DAPI (life Technologies, Carlsbad,
CA) was used as counter stain. The cells were then observed under the
fluorescence microscope.10
2.8 Tube Formation Assay
The HGMSCs were treated with 0, 10, 50 and 100 ng/ml VEGF for 7 days. 50 µL
of Matrigel (mixture of extracellular matrixes; laminin, nidogen, collagen and
heparan sulfate proteoglycans, Corning) was added to each of the 16 wells in a
96-well plate and incubated for 1 hour at 37°C to solidify. Cells were then
trypsinized and suspended. The suspended cells were seeded on top of the
Matrigel. After incubation for 0,1, 3, 6 and 12 hours, the capillary like structures
were examined under the microscope and pictures were captured using Cellsens
Standard Software.10 (Figure 9)
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Figure 9: Tube Formation Assay

2.9 Statistical Analysis
Statistical analysis was performed using the GraphPad Prism 5.0software
(GraphPad Software, La Jolla, CA, USA). Data presented in this study are means
± standard deviation of the mean.

For quantitative reverse transcriptase

polymerase chain reaction (qRT-PCR), relative gene expression ratios were
determined using the 2Δct mathematical model. Samples were analyzed at least
in five independent experiments (n=5) using triplicates at minimum for quantitative
PCR. For all other experiments three independent experiments (n=3) were
conducted. To evaluate differences between or among groups (control group and
experimental group), analysis of variance (ANOVA) was performed. In order for
statistical tests to be significant, a P-value < 0.05 is selected.
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CHAPTER 3 RESULTS
3.1 Isolation and Culture of Human Gingival Stem Cells
The isolated cells from the tissue were plated at a density of 2 x 10 4 cells/cm2 and
incubated with growth medium (DMEM supplemented with 10% FBS and 1%
antibiotics). The cells became 70 to 80% confluent after 3-5 days. The cells
showed homogenous, tightly adherent, spindle-shaped and fibroblast like
morphology.
3.2 Flow Cytometry Analysis
The cells obtained from passage 2 were subjected to flow cytometry. The flow
cytometry confirmed expression of surface markers CD105, CD90, CD73 (all
above 90%) and lack the expression of hematopoietic stem cell marker CD34.
(Figure 10)
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Figure 10: Flow Cytometry data showing surface markers of Mesenchymal Stem Cells. The
cells showed over 90% positive to CD73, CD90, CD105 and negative to CD34

3.3 Morphology of Cells after Induction of Angiogenic Medium
Cell morphology after VEGF treatment was monitored under light microscope.
Under phase contrast view, plated cells show spindle shaped structures at day 3
of induction with VEGF (Figure 11B). The cells shape is not exactly like that of
typical endothelial cells, so called cobble-stone appearance. Majority of cells still
showed fibroblast-like structure on the 7th day of differentiation. (Figure 11C)
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Figure 11: Morphology of cells after plating and after VEGF treatment on day 3 and 6

3.4 Scratch Assay
In- vitro Scratch assay was conducted to track the migration of endothelial cells.
The images were captured at the beginning, 4 hours and at 17 hours. Results
showed significant endothelial cell migration towards the scratch as compared to
control group (Undifferentiated GMSCs with CM only). At 0 hour, cells in
experimental group just started migrating. We observed more migration of cells in
experimental groups at 4 hours. At 17 hours, cells migration in VEGF induced cells
showed more than 90 % closure when compared to control (Figure 12).
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Figure 12: Scratch assay: Control group (CM) showed much slower migration of cells. 50
ng/ml VEGF induced GMSCs showed more than 90% closure at 17 hours.

3.5 Gene Expression Studies of Various Endothelial Markers of GMSCs
The expression of endothelial markers genes VEGF receptors (KDR, FLT-1),
PCDH12 VCAM-1, PECAM-1 were measured at day 7 post VEGF treatment. The
VEGF enhanced the gene expression of all endothelial markers in a dose
dependent manner. While VCAM-1 and KDR expression was significantly
upregulated at all concentrations (P= 0.0041, P= 0.003) respectively, the
upregulation of PCDH12 (P< 0.0001), FLT1 (P< 0.0001) and PECAM-1 (P< 0.03)
was maximum at the cells treated with 50ng/ml VEGF.

VCAM-1 expression

significantly increased 75 % at 10, 50 ng/ml and almost 100% increase at 100 ng/
ml (Figure 13). While KDR expression increased by significant 50 % and 75 % at
50 and 100 ng/ml respectively, there was no significant increase in the cells treated
with 10ng/ml compared to control (Figure 14). For PCDH12, the dose dependent
increase has been observed (Figure 15). As shown in Figure 16, for FLT-1, there
was 25 % and 50 % increase at 10 and 100 ng/ml respectively, and expression
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almost doubled at 50 ng/ml. Furthermore, PECAM-1 showed significant increase
of 50 % over the control at 50 ng/ml concentration (Figure 17). Overall, the results
demonstrated a dose dependent increase of endothelial markers. However, there
was no significant difference between 50ng/ml and 100ng/ml in any of the gene
expression. The relative gene expression of VCAM-1 has significantly increased
in GMSCs, however, the expression of all other genes was not comparable to
HUVEC cells (Data not shown).

VCAM-1
3.5

**

3

Fold difference

2.5
2
1.5
1
0.5
0
CM

10ng/ml

50ng/ml

100ng/ml

VEGF treatment (ng/ml)

Figure 13: GMSCs: Relative Gene Expression of VCAM-1 were analyzed 5 independent
times on 5 different donors, leading to p-value = 0.0041
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2
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VEGF Treatment (ng/ml)
Figure 14: GMSCs: Relative Gene Expression of KDR were analyzed 5 independent times
on 5 different donors, leading to p-value =0.003
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3.5
3

**
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2
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1
0.5
0
CM

10ng/ml
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Figure 15: GMSCs: Relative Gene Expression of PCDH12 were analyzed 5 independent
times on 5 different donors, leading to p-value <0.0001
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Figure 16: GMSCs: Relative Gene Expression of FLT-1 were analyzed 5 independent times
on 5 different donors, leading to p-value <0.0001

Figure 17: GMSCs: Relative Gene Expression of PECAM-1 were analyzed 5 independent
times on 5 different donors, leading to p-value <0.03
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3.6 Immunofluorescence Assay
Both HUVECs and GMSCs were treated with 50ng/ml of VEGF for one week. After
7 days, immunofluorescence assay performed to measure the expression of
PECAM-1. Immunofluorescence analysis demonstrated the expression of
PECAM-1 in differentiating GMSCs. Furthermore, results showed expression of
PECAM-1 in GMSCs is comparable with the expression in HUVECs. (Figure 18)

Figure 18: Immunofluorescence assay: Expression of PECAM-1 was observed in the cell
membranes of both GMSCs with 50 ng/ ml VEGF treatment and HUVECs. (Figures B, D).
Figure C and E showed magnified picture of cell for both VEGF induced gingival stem cells
and positive control. Negative control did not express PECAM-1 (Figure A)
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3.7 Tube Formation Assay
The functionality of the differentiating GMSCs angiogenic potential was assessed
in tube-forming assays, demonstrating that seeding of 3x103 cells on Matrigel
started forming tubes from 1 hour and it continued until 6 hours.
While the experimental group was the GMSCs induced with 10, 50 and 100 ng/ml
of VEGF for 7 days, the undifferentiated GMSCS (Cells treated with complete
medium at 0 ng/ml VEGF) served as control group. The functional behavior of the
differentiated cells showed more capillary like structures. Tube formation was
compared at 0, 1, 3 and 6 hours. At 0 hour, cells were just plated and all
concentrations look similar (Figure 19). At 1 hour, cells started organizing slightly
for tube formation in both control and experimental group. However, that was
prominent in the cells treated with 10 ng/ml and 50ng/ml (Figure 20). After 3 hours,
in 10 and 50 ng/ml, the cell clusters showed branching and tight interconnections,
while few capillaries were detected at 100 ng/ml concentration and no capillaries
formation was seen in control group (Figure 21). 6 hours afterwards, tube formation
was greatly enhanced at all concentrations. We observed increased density of cell
clusters at 10, 50 ng/ ml concentration. Tube formation interconnection was also
noticed in undifferentiated cells with CM only. At 100 ng/ ml, short tube formation
was observed and we noticed initiation of disintegration of capillaries (Figure 22).
After 12 hours, capillaries fully disintegrated and no more tube formation was
visible. (Figure 23)
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Figure 19: Tube formation assay at 0 hour: Cells just plated onto the Matrigel

Figure 20: Tube formation assay at 1 hour: Cells started organizing for
tube formation, however this was more prominent in cells at 10 and 50 ng/ml
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Figure 21: Tube formation assay at 3 hours: Cells started showing branching
and interconnections at 10 and 50 ng/ml, while few capillaries were detected at
100 ng/ml concentration. No capillaries formation was seen in undifferentiated
GMSCs at 0 ng/ml concentration (CM)

Figure 22: Tube formation assay at 6 hours: Tube formation was greatly
enhanced
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Figure 23: Tube formation assay at 12 hours: Capillaries disintegrated and no
more tube formation was visible
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CHAPTER 4 DISCUSSION AND CONCLUSIONS
4.1 Discussion
Mesenchymal stem cells (MSCs) are of great interest in regenerative medicine as
they have promising potential for clinical use. MSCs are pluripotent progenitors
that can differentiate into a variety of cell types while maintaining the self-renewal
property. Their applications have been extensively studied in bone tissue
engineering.

4,7-11

However, vascularization remains a challenge in bone tissue

engineering. Vasculature is essential for bone formation and bone remodeling
during fracture healing. Studies have shown that endothelial cells can enhance
bone regeneration ability.7 Mature endothelial cells have been used for
vascularization in bone tissue engineering, but these have limited proliferative
capacity and cells are not sufficient for repair and reconstruction of blood vessels
during bone regeneration.12 Sufficient evidences in the past indicate that
mesenchymal stem cells in- vitro have the potential to differentiate into endothelial
progenitor cells.9,10,41 Transdifferentiation of MSCs to endothelial cells have many
advantages as serve as autologous stem cell source with highly proliferative with
self-renewing capability. Differentiating MSCs to endothelial cells have added
advantage, as the endothelial progenitor cells are more proliferative than
differentiated endothelial cells.12 MSCs differentiating into endothelial cells have
been reported in bone marrow derived stem cells, adipose derived stem cells and
stem cells derived from Wharton’s jelly.7,10,12,41,42 The angiogenic differentiation of
dental pulp derived stem cells have been reported recently.43 Indeed, the stem
cells derived from dental tissue secrete angiogenic factors to stabilize vascular
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networks.43,44 VEGF has pivotal role on endothelial cell proliferation, migration and
initiating and regulating angiogenesis.6,13 Neovascularization induced by VEGF
represents an appealing approach for bone tissue engineering. Many scientists
explored the differentiation of MSCs utilizing VEGF. For example, Oswald et al.
reported the differentiation of human bone marrow -derived mesenchymal stem
cells to endothelial progenitor cells with VEGF activation.10 Similarly, Cao et al.
have demonstrated that the human adipose tissue-derived stem cells differentiated
into endothelial progenitor cells in-vitro with VEGF and b-FGF activation.9 These
evidences indicated that VEGF can support the differentiate mesenchymal stem
cells into endothelial progenitor cells (EPC). EPC have a higher survival rate and
10 times more proliferative as compared to mature endothelial cells. 7,12

In this

study, we have investigated the effect of vascular endothelial growth factor (VEGF)
to induce the differentiation of GMSCs into endothelial lineage.
Our approach is to utilize the minimal dose of VEGF to induce the angiogenic
differentiation in GMSCs. In this study, we used different concentrations of VEGF
(10, 50, 100 ng/ ml) were tested for its ability to induce endothelial differentiation
from GMSCs in vitro. After 7 days of VEGF treatment with different concentrations,
gene expression of angiogenic marker genes was measured using quantitative
PCR. To confirm the results immunofluorescence and tube formation assay was
conducted. The overall results indicated that VEGF induced stem cell
differentiation into endothelial like cells. The angiogenic differentiation medium that

37

we have used consists of DMEM with 10% Fetal Bovine Serum (FBS) and 1%
antibiotics supplemented with VEGF. Table 3 gives the details of culture conditions
of various researchers used.

Table 3: Culture Medium used in various studies

For example, Oswald et al used 2% FBS in the culture medium supplemented with
VEGF,10 however, in our study the cells we used 10% FBS in culture medium, as
our pilot study conducted with 2% and 5% FBS in culture media demonstrated that
the cells could not survive in low concentrations of FBS (either 2% or 5%). In our
study, we have initially used various concentrations of VEGF for gene expression
studies and tube formation assay. Our data revealed that 50ng/ml was the optimal
concentration at which the maximal upregulation of marker genes and vessel
formation observed. Hence, we used 50ng/ml for all other experiments.
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Cell migration is the coordinated movement of a group of cells that maintain the
inter cellular connections and collective polarity. Cell migration studies are
hallmark in angiogenesis, would healing and cancer invasion. It can be studied by
a variety of methods; one of the popular methods, which is very often used, is the
scratch assay or wound healing assay.38 Our studies indicated that VEGF
enhanced the cell migration compared to untreated cells. Our data is in agreement
with the studies of Fiedler et al.45 They demonstrated that VEGF participates
induce the migration of bone marrow derived progenitor cells. Cell migration is a
key understanding process in wound healing.46 Thus our studies indicated that
VEGF has a potential role inducing cell migration and wound healing process.45,46
VEGF is a key regulator of angiogenesis through cell migration and proliferation of
vascular endothelial cells.47 Many other researchers also demonstrated that VEGF
has a significant role in the cell migration.45,46 Our data showed that the cells
started migrating in VEGF treated cells and the migration rate increased over time
compared to control (cells treated with CM). The VEGF treated cells migrated and
almost 90 % closed the scratch 17 hours. A similar pattern was observed in several
earlier studies.38,39,45,46
The results of quantitative PCR demonstrated that the endothelial markers VCAM1, PECAM-1, KDR, FLT-1, PCDH12 in GMSCs induced with VEGF for 7 days
significantly upregulated compared to undifferentiated cells. When compared with
HUVEC cells, the VCAM-1 expression is strikingly significantly upregulated than
the expression in HUVEC cells. However, the expression of other genes was
significantly less than HUVEC cells grown in similar culture conditions. A similar
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pattern of down regulation was reported earlier, suggesting that a tissue specific
hierarchical pattern of gene expression.41 Duration of differentiation and the culture
medium used for angiogenic medium might be contributing factors. While
differentiation of Wharton’s Jelly derived stem cells cultured in M199 medium
occurred in 4 days, in SHED cultured in VEGF induced differentiation medium have
not expressed endothelial markers until 28 days.41,48 In dental pulp derived stem
cells (DPSC) cultured in EGM medium, and bone marrow stem cells cultured in
VEGF, basic fibroblast growth factor (bFGF), insulin like growth factor (IGF), and
epidermal growth factor (EGF) expressed angiogenic markers in 7 days and 14
days respectively.43,49 From these studies it is evident that culture medium and
duration of differentiation contribute important factors.
Angiogenesis is a tightly organized sequence of cellular events characterized
including endothelial cell migration, invasion and differentiation into capillaries.42
In vitro endothelial tube formation assays are used as a model for studying
endothelial differentiation. This assay is employed to determine the ability of
various compounds such as growth factors or drugs to promote or inhibit the tube
formation. Essentially, this assay measures the ability of cells plated at sub
confluent densities with appropriate extracellular matrix support to form capillary
like structures.42,49 Our data on tube formation assay revealed that VEGF induced
vascular like network in classical tube formation assay. GMSCs induced with
VEGF at 10 and 50 ng/ml formed the tubes with maximum at 6 hours. After 8
hours, the cells started clumping, and we could observe large clumps at 12-hour
time. Our studies revealed that after one hour they started migrating towards the
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center and start organizing tubule. A dose dependent trend has been seen in our
study. The tubes formed with dense branching at 10ng and 50 ng/ml. In 50 ng/ml
the tube density was maximum.
4.2 Conclusions
The regeneration of defect and lost tissue in oral region is the goal of our stem cell
research. For the first time, our study demonstrated that GMSCS were able to
differentiate into endothelial like cells. The advantage of utilizing the GMSCs
isolated from gingiva tissue is that, they are obtained as a discarded tissue in the
clinics during flap surgery procedures or third molar extractions. Furthermore, they
can serve as autologous stem cell source with robust proliferation rate and minimal
risk of immune-rejection. In addition to their neural crest origin, the high selfrenewal capacity, wound healing ability and their plasticity makes GMSCs suitable
for bone tissue engineering applications. On the contrary, the stem cells developed
from bone marrow cells require the invasive surgery. Additionally, the endothelial
differentiation ability of GMSCs, will expand their scope for many other tissue
engineering applications including bone and cardiac tissue engineering
applications. Thus, our study addressed, in part, the existing challenges to develop
a vascularized tissue engineered bone. Further, in vitro and in vivo studies are
warranted to gain more insights on the effects of VEGF as enhancer of
angiogenic/osteogenic coupling in stem cell based craniofacial bone regeneration.
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